IMEXHS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5 AUD | 0.00% |
|
0.00% | -25.37% |
| 04-25 | IMEXHS Completes AU$250,000 Conditional Placement | MT |
| 03-22 | IMEXHS Renews Two Enterprise Software Contracts; Shares Up 3% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.83 for the current period. Therefore, the company is undervalued.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -25.37% | 15.04M | - | ||
| +5.92% | 32.95B | C | ||
| +20.66% | 8.09B | C- | ||
| +25.15% | 4B | B- | ||
| -18.38% | 3.09B | C- | ||
| -19.61% | 1.39B | B | ||
| -31.26% | 1.19B | - | ||
| +8.02% | 966M | C | ||
| -33.44% | 933M | - | ||
| -26.12% | 834M | - | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- IME Stock
- Ratings ImExHS Limited